Activation of coagulation and platelets by candidate membranes of implantable devices in a whole blood model without soluble anticoagulant

Journal of Biomedical Materials Research - Part A

Volumn 101 A, Issue 2, 2013, Pages 575-581

  Sokolov, A ^a   Hellerud, B C ^a   Tonnessen T I ^b   Johannessen, E A ^c   Mollnes, T E ^a,d,e  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF SOUTH EASTERN NORWAY   (Norway)

^d NORDLAND HOSPITAL   (Norway)

^e UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Biocompatibility; Coagulation; Complement; Implantable device; Membrane

Indexed keywords

COMPLEMENT; ENZYME IMMUNOASSAY; IMPLANTABLE DEVICES; PLASMA SAMPLES; PLATELET ACTIVATION; POLYAMIDE MEMBRANES; THROMBUS FORMATION; WHOLE BLOOD;

AIRCRAFT ENGINE MANUFACTURE; BIOCOMPATIBILITY; BIOLOGICAL MATERIALS; COAGULATION; COATED MATERIALS; ENZYMES; MEMBRANES; PLATELETS;

IMPLANTS (SURGICAL);

BETA THROMBOGLOBULIN; ECULIZUMAB; HEPARIN; POLYAMIDE; POLYARYLETHERSULPHONE; POLYCARBONATE; PROTHROMBIN; SILICONE; SULFONE DERIVATIVE; THROMBIN ANTITHROMBIN COMPLEX; UNCLASSIFIED DRUG;

ARTICLE; ARTIFICIAL MEMBRANE; BLOOD CLOTTING; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME IMMUNOASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMPLANT; MATERIAL COATING; NORMAL HUMAN; THROMBOCYTE ACTIVATION;

ANTICOAGULANTS; ANTITHROMBIN III; BETA-THROMBOGLOBULIN; BLOOD COAGULATION; COMPLEMENT SYSTEM PROTEINS; HEPARIN; HUMANS; IMPLANTS, EXPERIMENTAL; MEMBRANES, ARTIFICIAL; MODELS, BIOLOGICAL; PEPTIDE FRAGMENTS; PEPTIDE HYDROLASES; PLATELET ACTIVATION; PROTHROMBIN;

EID: 84872676926     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.34348     Document Type: Article

References (50)

1. Clagett GP, Eberhart RC Artificial devices in clinical practice. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, editors. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia, PA: Lippincott; 1994. p1486-1505.
2. Vogler EA, Siedlecki CA Contact activation of blood-plasma coagulation. Biomaterials 2009; 30: 1857-1869.
3. Muthusubramaniam L, Lowe R, Fissell W.H., Li L., Marchant RE, Desai TA, Roy S. Hemocompatibility of silicon-based substrates for biomedical implant applications. Ann Biomed Eng 2011; 39: 1296-1305.
4. Paul D, Malsch G, Bossin E., Wiese F, Thomaneck U, Brown G.S., Werner H., Falkenhagen D. Chemical modification of cellulosic membranes and their blood compatibility. Artif Organs 1990; 14: 122-125.
5. Sokolov A, Hellerud BC, Johannessen E.A., Mollnes TE Inflammatory response induced by candidate biomaterials of an implantable microfabricated sensor. J Biomed Mater Res A 2012; 100: 1142-1150.
6. Ratner BD. Biomaterials Science: An Introduction to Materials in Medicine, 2nd ed, San Diego, CA: Elsevier Academic Press; 2004.
7. Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg 2009; 108: 1447-1452.
8. Gorbet MB, Sefton MV Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials 2004; 25: 5681-5703.
9. Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood 1996; 88: 3432-3445.
10. Hong J, Larsson A, Ekdahl K.N., Elgue G., Larsson R, Nilsson B. Contact between a polymer and whole blood: Sequence of events leading to thrombin generation. J Lab Clin Med 2001; 138: 139-145.
11. Andersson J, Ekdahl KN, Larsson R, Nilsson U.R., Nilsson B. C3 adsorbed to a polymer surface can form an initiating alternative pathway convertase. J Immunol 2002; 168: 5786-5791.
12. Ferraz N, Ott MK, Hong J. Time sequence of blood activation by nanoporous alumina: Studies on platelets and complement system. Microsc Res Tech 2010; 73: 1101-1109.
13. Sperling C, Fischer M, Maitz M.F., Werner C. Blood coagulation on biomaterials requires the combination of distinct activation processes. Biomaterials 2009; 30: 4447-4456.
14. Hong J, Nilsson EK, Reynolds H, Larsson R., Nilsson B. A new in vitro model to study interaction between whole blood and biomaterials. Biomaterials 1999; 20: 603-611.
15. Bowry SK, Courtney JM, Prentice C.R., Douglas JT Utilization of the platelet release reaction in the blood compatibility assessment of polymers. Biomaterials 1984; 5: 289-292.
16. Esmon CT. The impact of the inflammatory response on coagulation. Thromb Res 2004; 114: 321-327.
17. Ekdahl KN, Lambris JD, Elwing H, Ricklin D., Nilsson PH, Teramura Y, Nicholls IA, Nilsson B. Innate immunity activation on biomaterial surfaces: A mechanistic model and coping strategies. Adv Drug Deliv Rev 2011; 63: 1042-1050.
18. Markiewski MM, Nilsson B, Ekdahl K.N., Mollnes TE, Lambris JD Complement and coagulation: strangers or partners in crime? Trends Immunol 2007; 28: 184-192.
19. Lappegard KT, Christiansen D, Pharo A., Thorgersen EB, Hellerud BC, Lindstad J, Nielsen E.W., Bergseth G., Fadnes D, Abrahamsen TG, Hoiby E.A., Schejbel L., Garred P, Lambris JD, Harboe M, Mollnes TE. Human genetic deficiencies reveal the roles of complement in the inflammatory network: Lessons from nature. Proc Natl Acad Sci U S A 2009; 106: 15861-15866.
20. Lappegard KT, Fung M, Bergseth G., Riesenfeld J, Mollnes TE Artificial surface-induced cytokine synthesis: Effect of heparin coating and complement inhibition. Ann Thorac Surg 2004; 78: 38-44.
21. Hakim RM. Complement activation by biomaterials. Cardiovasc Pathol 1993; 2: S187-S197.
22. Mollnes TE, Brekke OL, Fung M, Fure H., Christiansen D, Bergseth G, Videm V., Lappegard KT, Kohl J, Lambris JD Essential role of the C5a receptor in E. Blood 2002; 100: 1869-1877.
23. Bexborn F, Engberg AE, Sandholm K, Mollnes T.E., Hong J., Nilsson EK Hirudin versus heparin for use in whole blood in vitro biocompatibility models. J Biomed Mater Res A 2009; 89: 951-959.
24. Sokolov A, Hellerud BC, Lambris J.D., Johannessen EA, Mollnes TE Activation of polymorphonuclear leukocytes by candidate biomaterials for an implantable glucose sensor. J Diabetes Sci Technol 2011; 5: 1490-1498.
25. Sokolov A, Hellerud BC, Pharo A, Johannessen E.A., Mollnes TE Complement activation by candidate biomaterials of an implantable microfabricated medical device. J Biomed Mater Res B Appl Biomater 2011; 98: 323-329.
26. Larm O, Larsson R, Olsson P. A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. Biomater Med Devices Artif Organs 1983; 11: 161-173.
27. Ovrum E, Mollnes TE, Fosse E, Holen E.A., Tangen G., Abdelnoor M, Ringdal MA, Oystese R, Venge P. Complement and granulocyte activation in two different types of heparinized extracorporeal circuits. J Thorac Cardiovasc Surg 1995; 110: 1623-1632.
28. Mollnes TE, Lea T, Froland S.S., Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985; 22: 197-202.
29. Mollnes TE, Redl H, Hogasen K., Bengtsson A, Garred P, Speilberg L., Lea T, Oppermann M, Gotze O., Schlag G. Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin Exp Immunol 1993; 91: 295-300.
30. Mollnes TE. Measurement of complement activation. Methods Mol Biol 2003; 225: 69-75.
31. Rother RP, Rollins SA, Mojcik C.F., Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007; 25: 1256-1264.
32. Woodruff TM, Nandakumar KS, Tedesco F. Inhibiting the C5-C5a receptor axis. Mol Immunol 2011; 48: 1631-1642.
33. Biological Evaluation of Medical Devices-Part 4: Selection of Tests for Interactions with Blood. Geneva: International Organization for Standardization (ISO); 10993-4: 2002.
34. Mollnes TE, Videm V, Christiansen D., Bergseth G, Riesenfeld J, Hovig T. Platelet compatibility of an artificial surface modified with functionally active heparin. Thromb Haemost 1999; 82: 1132-1136.
35. Brass LF. Thrombin and platelet activation. Chest 2003; 124: 18S-25S.
36. Thor A, Rasmusson L, Wennerberg A., Thomsen P, Hirsch JM, Nilsson B, Hong J. The role of whole blood in thrombin generation in contact with various titanium surfaces. Biomaterials 2007; 28: 966-974.
37. Cheung AK. Biocompatibility of hemodialysis membranes. J Am Soc Nephrol 1990; 1: 150-161.
38. Hakim RM, Fearon DT, Lazarus JM Biocompatibility of dialysis membranes: Effects of chronic complement activation. Kidney Int 1984; 26: 194-200.
39. Woffindin C, Hoenich NA Blood-membrane interactions during haemodialysis with cellulose and synthetic membranes. Biomaterials 1988; 9: 53-57.
40. Schultze G, Hollmann S, Sinah P. Formation of thrombin-antithrombin III complex using polyamide and hemophan dialyzers. Int J Artif Organs 1992; 15: 370-373.
41. Frank RD, Weber J, Dresbach H., Thelen H, Weiss C, Floege J. Role of contact system activation in hemodialyzer-induced thrombogenicity. Kidney Int 2001; 60: 1972-1981.
42. Walivaara B, Aronsson BO, Rodahl M, Lausmaa J., Tengvall P. Titanium with different oxides: In vitro studies of protein adsorption and contact activation. Biomaterials 1994; 15: 827-834.
43. Su BH, Fu P, Li Q., Tao Y, Li Z, Zao H.S., Zhao CS Evaluation of polyethersulfone highflux hemodialysis membrane in vitro and in vivo. J Mater Sci Mater Med 2008; 19: 745-751.
44. Krieter DH, Lemke HD Polyethersulfone as a high-performance membrane. Contrib Nephrol 2011; 173: 130-136.
45. Davies MI, Lunte CE Microdialysis sampling for hepatic metabolism studies. Drug Metab Dispos 1995; 23: 1072-1079.
46. Humpel C, Chadi G, Lippoldt A., Ganten D, Fuxe K, Olson L. Increase of basic fibroblast growth factor (bFGF, FGF-2) messenger RNA and protein following implantation of a microdialysis probe into rat hippocampus. Exp Brain Res 1994; 98: 229-237.
47. Ferraz N, Nilsson B, Hong J., Karlsson OM Nanoporesize affects complement activation. J Biomed Mater Res A 2008; 87: 575-581.
48. Lappegard KT, Fung M, Bergseth G., Riesenfeld J, Lambris JD, Videm V, Mollnes TE Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation. Ann Thorac Surg 2004; 77: 932-941.
49. Sperling C, Salchert K, Streller U., Werner C. Covalently immobilized thrombomodulin inhibits coagulation and complement activation of artificial surfaces in vitro. Biomaterials 2004; 25: 5101-5113.
50. Nilsson PH, Engberg AE, Back J, Faxalv L., Lindahl TL, Nilsson B, Ekdahl KN The creation of an antithrombotic surface by apyrase immobilization. Biomaterials 2010; 31: 4484-4491.